Effectiveness of Alzheimer's Universe (Www.AlzU.Org) on Knowledge and Behavior

Evaluating the Effectiveness of Web-based Education Via Alzheimer's Universe (Www.AlzU.Org) on Knowledge and Behavior: A Randomized Trial

To evaluate the effectiveness of an online educational course on Alzheimer's disease (AD) prevention, treatment and caregiving.

Study Overview

• Status: Withdrawn
• Conditions: Alzheimer Disease; Alzheimer Disease, Late Onset; Memory Loss; Patient Education as Topic
• Intervention / Treatment: Behavioral: Web-based education

Detailed Description

Alzheimer's Universe (www.AlzU.org) was created to provide online education about Alzheimer's disease (AD), with a focus on family members of people with AD, people with mild cognitive impairment due to AD and mild AD, caregivers, healthcare providers, medical students, college students and high school students. The website provides evidence-based courses with interactive lessons and activities that have been shown to increase knowledge about AD, willingness to participate in an AD prevention clinical trial, and intent to make specific lifestyle changes in effort to reduce AD risk.

• Study Type: Interventional
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • New York
    • New York, New York, United States, 10021
      • Weill Medical College of Cornell University

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 14 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: Yes
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• greater than or equal to 14 years old with a friend, family member or acquaintance with Alzheimer's disease or memory loss, OR a person diagnosed with mild memory loss (including mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease), OR an AD caregiver, OR healthcare providers, OR a medical student, college student or high school student.

Exclusion Criteria:

• < 14 years old, OR diagnosis of moderate or severe Alzheimer's disease

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Prevention
• Allocation: Randomized
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

2

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Intervention; Subjects will be given access to educational content on AD using interactive learning strategies	Behavioral: Web-based education; The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.
Sham Comparator: Time-neutral control; Subjects will be given access to time-neutral general educational content on AD	Behavioral: Web-based education; The investigators will utilize interactive lessons and activities to educate about Alzheimer's disease prevention, treatment and caregiving, with focus on evidence-based lifestyle and nutritional recommendations that have been associated with delaying cognitive decline.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Knowledge of AD Preventative behaviors	Knowledge is calculated as a positive change on multiple-choice questions about AD between pre vs. post-completion of educational material	12 months
Willingness to Engage in AD Preventative behaviors	Willingness is calculated as a positive change on questionnaires evaluating AD-preventative behaviors between pre vs. post-completion of educational material	12 months

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Participant Satisfaction	The investigators will assess general satisfaction with the educational modules via pre vs post-intervention participant surveys	12 months
Behavioral Assessments	The investigators will evaluate related behavioral assessments via pre vs post-intervention participant surveys	12 months

Collaborators and Investigators

• Sponsor: Weill Medical College of Cornell University
• Investigators: Principal Investigator: Richard Isaacson, MD, Weill Medical College of Cornell University

Publications and helpful links

Helpful Links

• Direct hyperlink to Alzheimer's Universe website

Study record dates

Study Major Dates

• Study Start (Anticipated): January 1, 2017
• Primary Completion (Anticipated): December 1, 2023
• Study Completion (Anticipated): October 1, 2024

Study Registration Dates

• First Submitted: January 13, 2017
• First Submitted That Met QC Criteria: May 10, 2017
• First Posted (Actual): May 11, 2017

Study Record Updates

• Last Update Posted (Actual): March 22, 2023
• Last Update Submitted That Met QC Criteria: March 20, 2023
• Last Verified: March 1, 2023

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Mental Disorders; Pathologic Processes; Brain Diseases; Central Nervous System Diseases; Nervous System Diseases; Neurologic Manifestations; Neurobehavioral Manifestations; Neurocognitive Disorders; Disease Attributes; Neurodegenerative Diseases; Dementia; Tauopathies; Alzheimer Disease; Late Onset Disorders; Memory Disorders
• Other Study ID Numbers: 1311014539

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: No